Retatrutide, a novel dual-acting glucose-dependent incretin agent, represents a significant advance in peptide treatments for the handling of type 2 diabetes and, increasingly, weight issues. Unlike many existing therapeutic interventions, retatrutide combines the actions of a GLP-1 receptor activator and a GIP receptor activator, offering a more h